Pharma Sector

Indian equity markets ended higher on May 22, 2026, supported by easing geopolitical tensions, declining crude oil prices, and a sharp recovery in the rupee. Banking and financial stocks led the rally, while Pharma, IT, and Media sectors remained under pressure amid selective profit booking and earnings reactions.

Indian benchmark indices staged a strong intraday recovery on May 18, 2026, despite a sharp opening selloff caused by escalating US-Iran tensions, Brent crude crossing $111 per barrel, and the rupee hitting record lows. IT and pharma stocks supported the rebound as Nifty and Sensex closed marginally in the green.

Gland Pharma reported a strong Q4 FY26 performance with net profit rising 96.6% YoY and revenue growing 22.3%. The stock rallied over 14% to hit a 52-week high as investors cheered margin expansion, strong CDMO momentum, and improving outlook for the injectables business.

The Indian benchmark indices staged a strong recovery on May 14, 2026, driven by strong quarterly earnings, bargain buying, and improving global sentiment. Pharma, healthcare, metal, and financial stocks witnessed robust gains, while IT shares remained under pressure due to rising concerns over AI-led disruption in the outsourcing sector. Cipla, Adani Enterprises, Bharti Airtel, and Zydus Lifesciences emerged among the top trending stocks of the day.

Cipla Q4 FY26 results were mixed, with a sharp decline in profit and margins offset by strong growth in India and Africa businesses. Despite weak North America performance, investor sentiment turned positive as adjusted earnings and dividends provided stability.

Sun Pharmaceutical Industries is set to acquire Organon & Co. in a $11.75 billion all-cash deal, driving its stock up 7% on the NSE. The acquisition enhances its global footprint, strengthens its women’s health portfolio, and marks a major entry into biosimilars.

After a week packed with major triggers like the Union Budget, the Indo-US trade deal, and the RBI policy, markets now turn to assessing real impact. The coming week will focus on how the trade deal affects exports, imports, currency risks, and overall market direction, along with key inflation and global data cues.

However, it is unclear whether the Hyderabad-based company will be Cobenfy's exclusive supplier.

Viyash manufactures active pharmaceutical ingredients (APIs) and drug formulations for the human health segment.

In August, the CDSCO banned more than 156 fixed-dose combination medications from the Indian market.